ArticleFrontiers in aging neuroscience2026
Focused ultrasound enhances targeted curcumin delivery and alleviates behavioral and neuropathological deficits in a Parkinson's disease mouse model.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Curcumin exhibits potent neuroprotective properties but is limited by poor blood-brain barrier (BBB) permeability. This study aimed to evaluate whether focused ultrasound (FUS)-mediated BBB opening enhances curcumin delivery and therapeutic efficacy in a 6-hydroxydopamine (6-OHDA) mouse model of Parkinson's disease (PD). Methods: Male C57BL/6 mice with unilateral 6-OHDA lesions received intravenous curcumin with or without FUS targeted to the lesioned striatum for 4 weeks. Behavioral performance was assessed using rotarod and open-field tests. Postmortem analyses included tyrosine hydroxylase (TH) immunostaining in the striatum and substantia nigra pars compacta (SNpc), glial fibrillary acidic protein expression, and fluorescence quantification of curcumin accumulation. Microglial activation and pro-inflammatory cytokine expression were evaluated using ionized calcium-binding adaptor molecule 1 (Iba1) and interleukin-6 (IL-6) staining. Safety was evaluated by histological examination for hemorrhage or necrosis. Results: Significant improvements in motor coordination and exploratory activity were observed in the FUS + curcumin group, particularly during early stages of degeneration. Histologically, combined treatment was associated with greater preservation of TH-positive dopaminergic neurons in the SNpc and reduced astrocytic activation in the striatum compared with curcumin alone, whereas striatal TH fiber density did not differ between curcumin-treated groups. No significant differences were observed in striatal Iba1 or IL-6 expression across groups at the 4-week time point. Enhanced curcumin accumulation in the brain was observed following FUS, as demonstrated by fluorescence quantification. No tissue damage or adverse effects were observed after repeated sonications. Discussion: This is the first study to demonstrate the efficacy of unmodified curcumin combined with FUS in a 6-OHDA PD model. The findings support FUS as a safe and effective strategy to transiently disrupt the BBB and enhance the central nervous system delivery of small-molecule therapeutic agents, offering translational potential for regionally targeted, non-invasive treatment of PD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.